Category: Press Releases

Capital will help accelerate JW Player’s growth and expand its already robust platform, empowering customers with independence and control in the Digital Video Economy

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) — JW Player, the leading video software and data insights platform, today announced it has raised $100M in Series E funding from LLR Partners. The latest investment comes on the heels of record video streaming growth and strong profitability during the previous 12 months. With this financing, JW Player will accelerate product innovation to meet the rapidly changing demands of customers in today’s digital video environment, expand its global go-to-market footprint across sales, marketing and channel partnerships and continue to grow and invest in building a world-class team.

The funding round follows JW Player’s recent acquisition of VUALTO, a leading provider of live and on-demand video streaming and Digital Rights Management (DRM) solutions, that deepened the company’s offering to global broadcasters. In the days following the acquisition, JW Player has seen a material uptick and influx of sales and pipeline, especially in the LATAM and APAC regions.

Started as a hugely-popular open source video player, JW Player’s API-driven video platform now empowers hundreds of thousands of customers to independently control and operate their mobile, OTT and Web video applications at global scale. Importantly, JW Player includes unique data-driven services and knowledge so that customers can more effectively grow and engage their audiences and generate more incremental revenue from their video investments. In the last year alone, the company’s video streaming grew by nearly 200%, while its live streaming delivery increased by over 400%.

This financing arrives as the consumption of digital video continues its push to the mainstream. Video now comprises over 80% of all traffic on the internet, and according to JW Player data, people are consuming over two hours of digital video each day, a 40% increase since the beginning of 2020. As a result, a digital video strategy has become a ‘must have’ not only for media companies, but also for organizations of all types, including fitness, e-commerce, sports and e-learning businesses, among others. These organizations have a diverse range of needs, require a flexible video platform that allows them to engage with their audiences on the screens of their choice and demand a quantifiable ROI from their video investments. Given these dynamics, the addressable market is on target to grow from $14B today to $50B by 2027, a 20% CAGR.

“Video has entered into a golden age, and we now live in the Digital Video Economy. By combining our easy-to-use video platform technology with our unique consumption and contextual data insights, JW Player has a distinct advantage in helping customers grow their audiences, create world-class video experiences on any screen, and most importantly, generate more revenue,” said Dave Otten, CEO and co-founder of JW Player. “As we enter this next phase, we are thrilled to partner with LLR. LLR’s team brings decades of unmatched support and expertise in growing industry-changing software companies and will undoubtedly help us accelerate our success as we pursue this massive market opportunity together.”

“JW Player has been at the forefront of digital video innovation ever since founder Jeroen Wijering created YouTube’s original video player in 2008. Today, the company offers the most comprehensive technology, advertising and data analytics platform in the digital video ecosystem,” said David Reuter, Partner at LLR Partners. “We look forward to partnering with the JW Player team as they expand their platform and continue to elevate the way brands can host, stream and monetize video.”

About JW Player
JW Player is the leading video software and data insights platform that gives customers independence and control in today’s Digital Video Economy. Started in 2008 as a hugely popular open-source video player, JW Player ’s technology platform now powers digital video for hundreds of thousands of businesses, including half of the comScore top 50 sites in the US, leading broadcasters across EMEA, APAC and Latin America. Each month 1 billion viewers, or one third of all people on the Internet, consume video on JW Player’s technology across 2.7 billion devices, creating an unmatched and powerful consumption and contextual data graph that helps customers grow audiences and generate incremental video from digital video. The company is headquartered in New York, with offices in London and Eindhoven, visit http://www.jwplayer.com.

About LLR Partners
LLR Partners is a middle market private equity firm investing in technology and healthcare businesses. We collaborate with our portfolio companies to identify and execute on key growth initiatives and help create long-term value. Founded in 1999 and with more than $5 billion raised across six funds, LLR is a flexible provider of equity capital for growth, recapitalizations and buyouts. Learn more at https://www.llrpartners.com/.

Media Contacts:
Fatimah Nouilati
Scratch Marketing + Media for JW Player
fatimah@scratchmm.com

Kristy DelMuto
LLR Partners
kdelmuto@llrpartners.com

Shuttle to operate remotely over Rogers 5G network thanks to one of several key research partnerships

Waterloo, Ontario, June 24, 2021 (GLOBE NEWSWIRE) — The University of Waterloo is showcasing the operation of a driverless, autonomous shuttle research program that will transport students and staff around campus.

The demonstration of the shuttle, dubbed “WATonoBus” by the research team, is the first of its kind at a Canadian academic institution and marks a significant milestone in a multi-year initiative to demonstrate and integrate autonomous transportation onto the campus.

This milestone features another significant technological advancement, as the shuttle becomes the first in the country to operate remotely over Rogers 5G network, thanks to a Rogers partnership agreement with the University to advance 5G research in the Toronto-Waterloo tech-corridor. This past September, as Rogers expanded Canada’s largest and most reliable 5G network to reach more communities, it lit up the University’s 5G Smart Campus to support researchers developing 5G applications and use cases in a real-world setting.

The shuttle’s 5-stop, 2.7-kilometre journey around the Waterloo main campus, intersecting with the campus light rail transit stop, holds the potential to help reshape how entire communities move around their urban spaces.

“We are thrilled not only about WATonoBus, but what it represents,” said Feridun Hamdullahpur, president and vice-chancellor of the University of Waterloo. “By marrying transformational research, infrastructure and a network of industry and government partnerships, we are demonstrating that educational institutions will help shape the future – in this case, the convergence of public transportation and smart urban mobility.”

The driverless shuttle with remote takeover capability will showcase a full-system approach, developed entirely at the University of Waterloo, led by Professor Amir Khajepour and a team of over 20 researchers in the Mechatronic Vehicle Systems Laboratory. Funding support has been provided by federal and provincial partners, as well as contributions from Applanix, RoboSense AI, and Rogers to make WATonoBus a reality.

The technology includes an integrated on-board sensor system providing vehicle intelligence and control; a suite of front, rear and side cameras providing a 360-degree view; light detection and ranging (LIDAR) active remote sensing systems used for detecting objects; and a WATonoBus smartphone app to help passengers navigate the campus using the shuttle.

“Today’s demonstration represents over four years of work with support and collaboration with government and industry partners,” Khajepour said. “This is an exciting step forward in autonomous, driverless public transportation.”

And, for the first time in Canada, an autonomous shuttle will be operated entirely on a remote basis using a 5G network. The modem on board will communicate through the Rogers 5G network with a research lab-based control centre. In the control centre, a remote operator will monitor the WATonoBus operations, and take over control when needed to ensure safe movement.

“As real-world 5G use cases such as the WATonoBus begin to take shape, we are starting to see the potential of 5G come to life,” said Jorge Fernandes, Chief Technology Officer at Rogers Communications. “Smart cities and smart transportation solutions are poised to help make cities safer, more efficient and more environmentally friendly. This example of 5G innovation demonstrates the importance of fostering 5G research and development to help fuel industries and drive Canada’s digital economy forward. We are proud to help enable this important 5G moment as part of our partnership with the University of Waterloo.”

Since lighting up the campus with 5G last year, Rogers has added next generation network technology and capabilities that will enable more intelligent and complex use cases and applications, including 5G mmWave (28GHz) small cells on campus, both inside buildings and outdoors, providing ultra-low latency and high bandwidth to support a variety of  5G research projects underway at the University.

The demonstration is the latest step of a multi-year initiative that is creating a testbed to evaluate automated driving on campus. Future industry partnerships will add more elements of a smart city on campus, a living testbed for advanced research, product development and data collection.

Before commencing operation as a regular service, the driverless shuttle system requires approval from the Ontario Ministry of Transportation (MTO). Currently, the University of Waterloo is a registered participant in Ontario’s Automated Vehicle Pilot Program, which permits testing of driverless AVs on Ontario roads provided a safety operator is on board.

Federal and provincial funding for the WATonoBus project has been provided through the Canadian Foundation for Innovation, the Ontario Research Fund and the Natural Sciences and Engineering Research Council.

Rebecca Elming
University of Waterloo
226-929-7627
relming@uwaterloo.ca

SmartEdge Partner Program Winners Are Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India and Enthu Technology Sdn. Bhd.

IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, today announced the winners of its SmartEdge™ Partner Program Awards. The awards were given at Lantronix’s 2021 SmartEdge Partner Summit held virtually on June 23, 2021.

Lantronix’s SmartEdge Partner Program Awards were given to winners in three categories: Distribution Partner, StrategicEdge Partner and Edge Partner covering three regions: North America, Europe/Middle East/Africa and Asia Pacific.

The winners are:
North America
North America Distributor Partner of the Year: Tech Data
North America StrategicEdge Partner of the Year: SHI
North America Edge Partner of the Year: Presidio

Europe/Middle East/Africa (EMEA)
EMEA Distributor Partner of the Year: Atlantik Elektronik
EMEA StrategicEdge Partner of the Year: Arki Technology
EMEA Edge Partner of the Year: Data Equipment

Asia Pacific (APAC)
APAC Distributor Partner of the Year: Acromax
APAC StrategicEdge Partner of the Year: Rahi Systems, India
APAC Edge Partner of the Year: Enthu Technology Sdn. Bhd.

“We are pleased to honor the SmartEdge Partner Program winners, all of which have exceeded our program requirements and expectations in driving sales and building long-term relationships with our mutual customers,” said Roger Holliday, VP of WW Sales at Lantronix.

SmartEdge Partner Program One-Year Anniversary

Lantronix celebrated the one-year anniversary of its new SmartEdge Partner Program in April 2021. “The Lantronix SmartEdge Partner Program has attracted the industry’s top channel partners,” said Jonathan Shipman, VP of Strategy at Lantronix. “With our SmartEdge Program, our channel partners offer Lantronix’s integrated offering of software, hardware and service solutions, providing their customers with everything they need to build robust, secure connectivity-based solutions.”

Lantronix Named to CRN Partner Program Guide

Lantronix’s SmartEdge Partner Program has been named to the industry’s leading partner program guide, the CRN Partner Program Guide. Published by CRN^®, a brand of The Channel Company, this annual guide provides a conclusive list of the most distinguished partner programs from leading technology companies that provide products and services through the IT Channel. The 2021 Partner Program Guide is online at www.CRN.com/PPG.

About the SmartEdge Partner Program

Lantronix’s SmartEdge™ Partner Program was designed to help Value-Added Resellers (VARs) and Systems Integrators (SIs) drive revenues by differentiating their offerings with Lantronix’s innovative Industrial Internet of Things (IoT), Remote Environment Management (REM), Out-of-Band Management (OOBM) and Mobility/Connectivity solutions.
For more information on the Lantronix SmartEdge Partner Program, visit www.lantronix.com/partners.

About Lantronix

Lantronix Inc. is a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM), offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware. Lantronix enables its customers to provide reliable and secure solutions while accelerating their time to market. Lantronix’s products and services dramatically simplify operations through the creation, development, deployment and management of customer projects at scale while providing quality, reliability and security.

With three decades of proven experience in creating robust IoT technologies and OOBM solutions, Lantronix is an innovator in enabling its customers to build new business models, leverage greater efficiencies and realize the possibilities of the Internet of Things. Lantronix’s solutions are deployed inside millions of machines at data centers, offices and remote sites serving a wide range of industries, including energy, agriculture, medical, security, manufacturing, distribution, transportation, retail, financial, environmental and government.

Lantronix is headquartered in Irvine, Calif. For more information, visit www.lantronix.com. Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this news release that are not entirely historical and factual in nature, including without limitation statements related to our solutions, technologies and products are forward-looking statements. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; the impact of the COVID-19 outbreak on our employees, supply and distribution chains, and the global economy; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. The forward-looking statements included in this release speak only as of the date hereof, and we do not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.

© 2021 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark, and EMG and ConsoleFlow are trademarks of Lantronix Inc. Other trademarks and trade names are those of their respective owners.

© 2021. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
media@lantronix.com
949-453-7158

Lantronix Analyst and Investor Contact:
Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
949-450-7241

Lantronix Sales:
sales@lantronix.com
Americas +1 (800) 422-7055 (US and Canada) or +1 949-453-3990
Europe, Middle East and Africa +31 (0)76 52 36 744
Asia Pacific + 852 3428-2338
China + 86 21-6237-8868
Japan +81 (0) 50-1354-6201
India +91 994-551-2488

ข้อตกลงใหม่ขยายขอบเขตการเข้าถึงทั่วโลกของ Conformis และนำระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมเฉพาะผู้ป่วยไปสู่ตลาดที่ใหญ่ที่สุดในภูมิภาคเอเชียแปซิฟิก

BILLERICA, Mass., June 24, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) วันนี้ได้ประกาศการดำเนินการตามข้อตกลงเพื่อเข้าสู่ตลาดเอเชียแปซิฟิกผ่านความสัมพันธ์การจัดจำหน่ายแบบเอกสิทธิ์เฉพาะบุคคลกับ XR Medical Group (Hong Kong) Limited (XR Medical)

ภายใต้ข้อตกลงการจัดจำหน่าย XR Medical จะได้รับสิทธิพิเศษในการขาย ทำการตลาด และการจัดจำหน่ายระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมแบบทั้งหมด iTotal^® CR & PS เฉพาะผู้ป่วยของ Conformis, อุปกรณ์สำหรับกระดูกสะบ้า iTotal^® CR & PS และระบบการผ่าตัดข้อเข่าเทียมชนิดบางส่วน iUni^® และ iDuo^® ผลิตภัณฑ์อื่นๆ เช่น ระบบสำหรับหัวเข่า Identity Imprint™ ที่ได้รับอนุมัติเมื่อไม่นานมานี้ของ Conformis และกลุ่มผลิตภัณฑ์สำหรับสะโพกของบริษัท ซึ่งอาจถูกเพิ่มเข้ามาในอนาคต

ทีมงานฝ่ายขายของ XR Medical จะมอบการขายและการสนับสนุนเฉพาะสำหรับสิ่งอำนวยความสะดวกระดับสูงใน Boao Lecheng International Medical Tourism Pilot Zone (เขตการค้าเสรีนำร่อง) ของไห่หนานในนามของ Conformis ภูมิภาคนี้เป็นศูนย์กลางการท่องเที่ยวทางการแพทย์ที่สำคัญสำหรับหลายสิบประเทศ

“ข้อตกลงการจัดจำหน่ายนี้เป็นอีกตัวอย่างหนึ่งของความคืบหน้าในขณะที่เราดำเนินกลยุทธ์การเติบโตโดยรวมของเรา เรามั่นใจว่ากลุ่มผลิตภัณฑ์ที่โดดเด่นของเราจะช่วยเร่งความเติบโตระดับสากลของ Conformis ได้ และเรายินดีที่จะเป็นพันธมิตรกับ XR Medical ซึ่งมีประวัติความสำเร็จที่น่าประทับใจในประเทศจีน” Mark Augusti ประธานและ CEO ของ Conformis กล่าว “สิ่งที่น่าสนใจเป็นพิเศษเกี่ยวกับ XR Medical คือประสิทธิภาพที่แข็งแกร่งในเขตการค้าเสรีนำร่อง ด้วยการเข้าถึงผู้ป่วยที่เข้ามาในภูมิภาคเพื่อรับการรักษา จะทำให้เกิดโอกาสที่จะแนะนำกลุ่มเป้าหมายที่กว้างขวางเกี่ยวกับประโยชน์ทางคลินิกของเทคโนโลยี Conformis เราเชื่อว่าการเริ่มต้นในเขตการค้าเสรีนำร่องทำให้เราอยู่ในตำแหน่งที่ดี และเราคาดว่าความสัมพันธ์นี้จะเป็นแบบอย่างสำหรับโอกาสในการขยายตัวในอนาคตในจีนแผ่นดินใหญ่”

เขตการค้าเสรีนำร่องตั้งอยู่บนไหหลำ ซึ่งเป็นเกาะขนาดใหญ่นอกชายฝั่งทางใต้ของจีน ซึ่งจัดตั้งขึ้นในปี 2019 เพื่อดึงดูดพลเมืองชาวจีนที่มีฐานะมั่งคั่งซึ่งอาจจะไปต่างประเทศเพื่อรับการดูแลทางการการแพทย์ เขตภูมิภาคนี้ของจีนได้พัฒนาสถานรักษาพยาบาลระดับสูงในจุดหมายปลายทางยอดนิยม ปัจจุบัน นักท่องเที่ยวทางการแพทย์จากหลายสิบประเทศ รวมทั้งในเอเชียตะวันออกเฉียงใต้ ได้รับอนุญาตให้เข้าพักที่ไหหลำได้ 30 วันโดยไม่ต้องขอวีซ่า

ตลาดโลกสำหรับการฟื้นฟูข้อเข่าคาดว่าจะมีมูลค่ามากกว่า 9 พันล้านดอลลาร์ จากทั้งหมดนี้ คาดว่าตลาดการฟื้นฟูข้อเข่าในภูมิภาคเอเชียแปซิฟิกในปัจจุบันจะมีมูลค่าเกิน 1.7 พันล้านดอลลาร์ Fortune Business Insights คาดการณ์อัตราการเติบโตสูงสำหรับการผ่าตัดเปลี่ยนข้อเข่าเทียมในภูมิภาคนี้ อันเนื่องมาจากจำนวนของอาการข้อเข่าเสื่อมที่เพิ่มขึ้น การท่องเที่ยวเชิงการแพทย์ที่เฟื่องฟู รายได้ที่เพิ่มขึ้น และโครงสร้างพื้นฐานด้านการดูแลสุขภาพที่ดีขึ้น

เกี่ยวกับ Conformis, Inc.

Conformis เป็นบริษัทเทคโนโลยีทางการแพทย์ที่ใช้แพลตฟอร์มเทคโนโลยี iFit^® Image-to-Implant® ที่เป็นกรรมสิทธิ์ เพื่อพัฒนา ผลิต และจำหน่ายการปลูกถ่ายและอุปกรณ์สำหรับข้อเข่าที่มีขนาดและรูปทรงแตกต่างกัน ซึ่งเราหมายความว่าเป็นส่วนบุคคล เฉพาะบุคคล หรือบางครั้งก็หมายความว่าปรับแต่งเอง เพื่อให้เหมาะสมและสอดคล้องกับกายวิภาคของผู้ป่วยแต่ละราย Conformis นำเสนอผลิตภัณฑ์ปลูกถ่ายข้อเข่าและสะโพกเฉพาะบุคคลและผลิตภัณฑ์ปลูกถ่ายแบบมาตรฐานหลากหลายที่ปลอดเชื้อ พร้อมด้วยเครื่องมือแบบใช้ครั้งเดียวที่ส่งไปยังโรงพยาบาลและศูนย์ศัลยกรรมผู้ป่วยนอก ในการศึกษาทางคลินิก ระบบการผ่าตัดเปลี่ยนข้อเข่าเทียม Conformis iTotal^® CR แสดงให้เห็นผลลัพธ์ทางคลินิกที่เหนือกว่า รวมถึงการทำงานที่ดีขึ้นและความพึงพอใจของผู้ป่วยมากกว่า เมื่อเทียบกับการปลูกถ่ายแบบดั้งเดิมที่มีจำหน่ายตามท้องตลาด Conformis เป็นเจ้าของหรือผู้ที่ได้รับสิทธิบัตรหรือการใช้งานที่อยู่ระหว่างการจดสิทธิบัตรที่รอดำเนินการ ซึ่งครอบคลุมการปลูกถ่ายส่วนบุคคลและเครื่องมือเฉพาะของผู้ป่วยสำหรับข้อต่อที่สำคัญทั้งหมด

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.conformis.com หากต้องการรับการแจ้งเตือนทางอีเมลในอนาคต โปรดลงทะเบียนที่ http://ir.conformis.com

หมายเหตุข้อควรระวังเกี่ยวกับข้อความเชิงคาดการณ์เหตุการณ์ในอนาคต

ข้อความในข่าวประชาสัมพันธ์ฉบับนี้เกี่ยวกับความคาดหวัง แผนงาน และแนวโน้มในอนาคตของเรา ตลอดจนข้อความอื่นๆ ที่มีคำว่า “คาดการณ์”, “เชื่อ”, “ดำเนินการต่อ”, “สามารถ”, “ประมาณ”, “คาดว่า”, “ตั้งใจ”, “อาจจะ”, “อาจ”, “วางแผน”, “มีแนวโน้ม”, “คาดเดา”, “มีโครงการ”, “ควรจะ”, “เป้าหมาย”, “จะ” หรือ “น่าจะ” และสำนวนที่คล้ายคลึงกันถือเป็นข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตตามความหมายของบทบัญญัติการจำกัดความรับผิดชอบของกฎหมายปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี 1995 คุณไม่ควรเชื่อถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตมากเกินไป ผลลัพธ์ที่แท้จริงอาจแตกต่างอย่างมากจากการคาดการณ์ที่เปิดเผยในข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่เราทำอันเป็นผลมาจากความเสี่ยงและความไม่แน่นอนต่างๆ รวมถึงความเสี่ยงและความไม่แน่นอนที่อธิบายไว้ในส่วน “ปัจจัยเสี่ยง” ของเอกสารที่ยื่นต่อสาธารณะของเรากับสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ นอกจากนี้ ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่รวมอยู่ในข่าวประชาสัมพันธ์ฉบับนี้แสดงถึงมุมมองของเรา ณ วันที่ในที่นี้ เราคาดหวังว่าเหตุการณ์และการพัฒนาที่ตามมาอาจส่งผลให้มุมมองของเราเปลี่ยนแปลงได้ อย่างไรก็ตาม ในขณะที่เราอาจเลือกที่จะปรับปรุงข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ในบางจุดในอนาคต เราขอปฏิเสธภาระผูกพันใดๆ ที่จะต้องดำเนินการดังกล่าว ไม่ควรยึดถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ว่าเป็นการแสดงความเห็นของเรา ณ วันที่ใดๆ ต่อจากวันที่ในที่นี้

ที่มา: Conformis, Inc.

ติดต่อด้านสื่อ:
ข้อมูลติดต่อสำหรับนักลงทุนสัมพันธ์
ir@conformis.com
(781) 374-5598

TeraRecon Announces Dan McSweeney President

DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) — Advanced visualization and AI leader TeraRecon, a SymphonyAI company, today announced the appointment of Dan McSweeney as president. He will be responsible for continuing and expanding TeraRecon’s leadership in healthcare advanced visualization and enterprise AI.

“TeraRecon is known for its strong reputation as the leader in advanced visualization and AI innovation in healthcare,” said McSweeney. “We are reinvesting the benefits of that leadership into delivering further value for organizations by maintaining excellence in advanced visualization and clinical workflow applications, as well as implementing next-gen, AI-based technologies for superior outcomes for patients and communities.”

TeraRecon leads the medical advanced visualization and AI market with its flagship Intuition product, delivering real-time imaging decision support for radiology, cardiology, vascular surgery, and more. Intuition is the 3D imaging market share leader in the US and the 2021 KLAS category leader for advanced visualization.

“TeraRecon has a long history of innovation and delivering customer value. Dan will help TeraRecon build on this history by accelerating AI-driven visualization and clinical solutions,” said Romesh Wadhwani, chairman and founder of TeraRecon’s parent company, SymphonyAI. “Dan’s track record of creating and expanding value through continuous solution improvement and deployment will serve the TeraRecon team well. He understands the importance of driving down barriers to adoption by making AI solutions valuable, practical, and ubiquitous.”

McSweeney brings to TeraRecon more than 20 years of strategic healthcare experience, with a strong track record of customer-centric growth. He spent 18 years with GE Capital and GE Healthcare in multiple executive roles. Most recently, he was at Wolters Kluwer Health, where he led the company’s $500 million business in the Americas.

About TeraRecon: TeraRecon, a SymphonyAI business, is a leader in advanced imaging and visualization AI and clinical AI solutions with a mission to continuously redefine patient and healthcare. The flagship Intuition product is the 2021 KLAS category leader for advanced visualization and holds the number one market share in 3D imaging in the US. TeraRecon is continuing to innovate ahead of customer demand with sophisticated healthcare-focused AI platform solutions unlike any in the world today.

About SymphonyAI

SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth verticals, including life sciences, healthcare, retail, consumer packaged goods, financial services, manufacturing, and media. In each of these verticals, SAI businesses have many of the leading enterprises as clients. SAI is backed by a $1 billion commitment from Dr. Romesh Wadhwani, a successful entrepreneur and philanthropist. Since its founding in 2017, SymphonyAI has grown rapidly to over 2,200 talented leaders, data scientists, and other professionals.

For more information, visit www.terarecon.com or info@terarecon.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f634d796-76e4-4209-871b-ee8a912b4f69

XIAN, China, June 23, 2021 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the pricing of its firm commitment initial public offering of 2,200,000 ordinary shares, par value US$0.0001 per share (the “Shares”) at a public offering price of $5.00 per Share (the “Offering”), for total gross proceeds of $11.0 million, before deducting underwriting discounts, commissions and other related expenses. In addition, BON has granted the underwriters a 45-day option to purchase up to an additional 330,000 Shares at the public offering price, less underwriting discount and commissions. The Shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “BON” on June 24, 2021. The Offering is expected to close on or about June 28, 2021, subject to the satisfaction of customary closing conditions.

The Company intends to use the proceeds for working capital, to expand their sales and distribution network, research and development, and to expand production capacity.

U.S. Tiger Securities, Inc. and Newbridge Securities Corporation are acting as co-lead book running managers, and R.F. Lafferty & Co. Inc. is acting as the joint lead book running manager.

The Company’s securities described above are being offered pursuant to an effective registration statement on Form F-1 (SEC File No. 333-251182), that was previously filed with the Securities and Exchange Commission (“SEC”) on May 14, 2021, subsequently amended and declared effective on June 23, 2021, a copy of which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The Offering is being made only by means of such prospectus.

This press release contains information about the pending Offering of securities, and there can be no assurance that the Offering will be completed.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Bon Natural Life Limited

The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the natural, health and personal care market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

In the United States:	In China:
Maggie Zhang | Impact IR	Sophie Zhang| Impact IR
Phone: (646) 893-8916
Email: maggie.zhang@irimpact.com	Email: sophie.zhang@irimpact.com

New additions reflect the diverse, global perspective of the business school community

RESTON, Va., June 23, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of four new members to its board of directors. Katy Montgomery, Associate Dean, Degree Programmes, INSEAD; François Ortalo-Magné, Dean, London Business School; and Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University, will begin their terms on July 1. In addition, Yuan Ding, Vice President and Dean of China Europe International Business School (CEIBS), was appointed as a board director in January this year to fill the seat vacated by Enase Okonedo of the Pan-Atlantic University.

“GMAC’s new board of directors represent leading business schools with campuses located in 10 countries across Europe, Asia, North America, Africa, and the Middle East,” said Sangeet Chowfla, president and CEO of GMAC. “As student mobility returns and regains in the post-pandemic world, I look forward to working alongside this diverse group of leaders ― and the rest of the GMAC board ― to continue to advance GMAC’s vision to ensure that all talented individuals can benefit from the best business education for them.”

New GMAC Board Members

Yuan Ding, Vice President and Dean, Cathay Capital Chair in Accounting, CEIBS

Yuan Ding is Vice President and Dean and the Cathay Capital Chair Professor in Accounting at CEIBS, where he has been honored three times with the CEIBS Teaching Excellence Award. Prior to joining CEIBS, he was a tenured faculty member of the HEC School of Management, Paris, France. He is a member of the European Accounting Association, French Accounting Association and American Accounting Association. He holds a PhD in Accounting from the Institute of Enterprises Administration at the University Montesquieu Bordeaux IV, France, as well as a Master’s in Enterprises Administration from the University of Poitiers, France. Ding is the author of multiple books on financial reporting and his research appears in leading academic journals.

Katy Montgomery, Associate Dean, Degree Programmes, INSEAD

As the INSEAD Associate Dean of Degree Programmes, Montgomery is responsible for the commercial leadership of the INSEAD Degree Programme portfolio across four campuses: Fontainebleau, Singapore, Abu Dhabi, and San Francisco. Her functional responsibilities include strategy, marketing, sales, admissions, financial aid and scholarships, programme operations, student life, psychological services, and career services. Prior to joining INSEAD, she served as Associate Dean of Student Development at Johns Hopkins Carey Business School. Montgomery holds a degree in Political Science from Loyola University New Orleans and a Juris Doctor degree from Georgetown University Law Center.

François Ortalo-Magné, Dean, London Business School

François Ortalo-Magné is the ninth Dean of London Business School (LBS), a position he has held since August 2017. He is leading a strategy focused on (1) academic research and its impact, (2) learning innovations and alumni engagement and (3) inclusion, striving for gender parity and greater socio-economic and ethnic diversity. Since taking up the role, Ortalo-Magné has led the relaunch of the LBS brand, the growth of degree programmes and a significant increase in philanthropic support for scholarships. His research on the economics of land and housing markets has been published in leading academic journals. He has built on his research and leadership experiences to advise a broad range of private, governmental and multi-lateral organisations and share his insights in leading media outlets and at conferences around the world. Prior to his appointment, Ortalo-Magné was the Albert O. Nicholas Dean and Robert E. Wangard Professor of Real Estate at the Wisconsin School of Business. His first academic appointment was at the London School of Economics.

Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University

Giuseppe “Beppe” Soda is the Dean of SDA Bocconi School of Management and Full Professor of Organization Theory and Network Analysis at Bocconi University. Before becoming Dean in 2016, his roles have included serving as the Associate Dean for Research (2007-2013), Director of the Department of Management and Technology (2013-2016) and Head of Organization and HRM Department (2001-2006). He is also serving EFMD as member of the EQUIS Accreditation Board. Soda’s research investigates the performance consequences of the interplay between organizational architectures and organizational networks and his work has been published in top academic management journals.

Besides the aforementioned newly elected board members, Martin Boehm, Professor of Marketing and former Dean of IE Business School and soon the new Rector of EBS Universität für Wirtschaft und Recht, and Themin Suwardy, Dean of Postgraduate Professional Programmes, Singapore Management University, were re-elected for a second term.

GMAC also recognizes its outgoing board members, Leila Guerra, Vice Dean (Education) of Imperial College Business School, and Peter Tufano, Peter Moores Dean and Professor of Finance of Saïd Business School, University of Oxford. GMAC thanks them for their service in the past nearly four years to our organization and contributions to the graduate management education community.

About GMAC™

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com.

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)
thsu@gmac.com

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”

ABOUT RAPIDPULSE

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit www.rapidpulsemed.com for more information.

ABOUT SANTÉ VENTURES

Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit sante.com.

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit www.epidarex.com

ABOUT HATTERAS VENTURE PARTNERS

Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit www.hatterasvp.com.

ABOUT BROADVIEW VENTURES

Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit broadviewventures.org.

MEDIA CONTACT:

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility

TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) — Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness.

“AGC is a high-quality partner with global manufacturing expertise, and we are pleased to extend our long-standing relationship as we continue to progress in our clinical development,” said Adi Mor, Chief Executive Officer. “CM-101 has tremendous potential in treating fibrosis and inflammation, and we are excited to continue to scale up our manufacturing capacity ahead of our Phase 3 registration-enabling trials.”

Mark Womack, Chief Business Officer at AGC Biologics added, “We are very pleased that Chemomab has entrusted us to manufacture CM-101, following successful delivery of the early phase supply. Our Copenhagen site has the proven experience and expertise to help Chemomab in its journey towards market supply of this important therapy.”

“The Copenhagen team is excited to help advance the manufacturing process for CM-101 to the next phase, and is looking forward to a close collaboration with the Chemomab team,” says AGC Biologics General Manager, Copenhagen, Andrea C. Porchia.

AGC Biologics’ Copenhagen facility has over 20 years’ experience delivering a wide range of mammalian and microbial programs, including several commercially approved products. The news comes less than seven months after the announcement of a €160M expansion project that would double the production capacity in Denmark to address increasing market demand.

About CM-101 
CM-101 is a first-in-class monoclonal antibody that targets CCL24 and has been shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.  Pre-clinical evidence has shown CM-101 to be an effective therapy with potential to fill the gap in today’s fibrotic disease care. CM-101 has been well-tolerated in healthy subjects and in NAFLD patients via intravenous or subcutaneous administrations. Both routes of administration support long dosing intervals and provide evidence of target engagement and biological activity in humans. CM-101 Phase 2 safety and efficacy trials in patients with PSC and Liver fibrosis (NASH) are currently ongoing and a third Ph2, in Systemic sclerosis, is expected to initiate by the end of 2021.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,700 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

About Chemomab Therapeutics Ltd. 
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
For more information on Chemomab, please visit www.chemomab.com.

Forward Looking Statements 
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab’s current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: the uncertain and time-consuming regulatory approval process; risks related to Chemomab’s ability to correctly manage its operating expenses and its expenses; Chemomab’s plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab’s planned clinical trials; the timing of the availability of data from Chemomab’s clinical trials; the timing of any planned investigational new drug application or new drug application; Chemomab’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab’s product candidates; Chemomab’s commercialization, marketing and manufacturing capabilities and strategy; Chemomab’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab’s and its business can be found under the caption “Risk Factors” and elsewhere in Chemomab’s filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

AGC Biologics Contact:
Media Contact: Matteo Pellegrino
mpellegrino@agcbio.com
http://www.agcbio.com/

Chemomab Therapeutics Ltd.

Investor Relations:
Irina Koffler
LifeSci Advisor, LLC
Phone: +1-917-734-7387
ir@chemomab.com

Chemomab Therapeutics:
Sharon Elkobi 
VP, Business Development
Phone: +972773310156
bd@chemomab.com

Matteo Pellegrino
AGC Biologics
mpellegrino@agcbio.com